About

Chugai Group’s mission is to create innovative drugs for the benefit of patients.

Message from the CEO

Futa Mimoto PH.D.

Director, Chief Executive Officer

At Chugai Pharmabody Research (CPR) our drug discovery efforts are driven by our mission to advance patient-centric healthcare. As a core research institute of Chugai Pharmaceutical, a member of the Roche Group, we are committed to developing innovative drugs that can unlock new therapeutic possibilities for patients with unmet medical needs.

Over the past decade, we have leveraged our proprietary antibody engineering and cyclic peptide technologies to develop promising drug candidates. This includes breakthrough antibody therapy treatment for paroxysmal nocturnal hemoglobinuria, which has achieved regulatory approval in Japan, Europe, and the US. This milestone reinforces CPR’s position as a global leader in drug discovery.

Our success is deeply rooted in Singapore’s vibrant science ecosystem. We have thrived thanks to Singapore’s robust research infrastructure, access to a diverse pool of highly trained multinational scientists, and supportive policies that advance biomedical research.

Looking ahead, we remain focused on developing groundbreaking medicines that can transform patient care. We will continue to nurture a workplace where our people can amplify their impact through their research.

Building strong, trusted research partnerships remains a priority. Our joint research with the Agency for Science, Technology and Research (A*STAR) on the development of anti-dengue virus and COVID-19 antibodies reflect how such collaborations can transform unique research into tangible therapies.

By deepening collaborations, we aim to advance innovative therapies and support the ongoing growth of Singapore’s science ecosystem for shared, sustainable success.

OUR VISION

We aim to create innovative drug against the disease with high unmet medical needs for the human health around the world.

We will become a top innovator to realise advanced and sustainable patient-centric healthcare by our unique strength in science and technology with our highly diverse group of people having inclusive mind-set.

OUR MISSION

We create antibody drug clinical candidates using our proprietary antibody engineering technology platforms, and support drug development towards clinical development.

We identify biologically active cyclic peptide binders using our proprietary display technology platforms.

We develop innovative engineering technologies of proteins and cyclic peptides to create drugs even for difficult target molecules.

CORE VALUE

Patient Centric
Make each patient’s well-being our highest priority.

Pioneering Spirit
Pursue innovation by improving ourselves and thinking differently.

Integrity
Maintain the highest standards in all we do to create shared value with society.

Company Profile

Chugai Pharmabody Research (CPR) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd. (“Chugai”), Japan’ s No.1 biopharmaceutical company, and a member of Roche group, in January 2012 and started operations on July 2, 2012.

CPR conducts drug discovery research creating new antibody drug clinical candidates focusing on high value First-in-Class and Best-in-Class antibodies for a variety of targets and diseases using our proprietary antibody engineering technologies. CPR also conducts research utilizing our cyclic peptide drug discovery platform.

Company Name

Chugai Pharmabody Research Pte. Ltd.
(“Pharmabody” is coined from the words pharmaceutical and antibody.)

Establishment

January 10, 2012

Location

3 Biopolis Drive, #07–11 to 16 Synapse, Singapore 138623

Commencement of Operations

July 2, 2012

Capital

S$ 1.5 million

CEO

Futa Mimoto Ph.D.

Shareholder

Wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd.

Board of Directors

Sir David Lane, Chairman of the Board,

Futa Mimoto, Director and CEO
Hitoshi Iikura, Director
Ashok Venkitaraman, Director

Number of Employees

155 employees

History

“”

1925

Juzo Ueno founded Chugai Shinkyaku Co., Ltd. and began the import and sale of medicinal drugs.

“”

1943

Reorganized into a corporation and company name changed to Chugai Pharmaceutical Co., Ltd. (Photo of Matsunage Plant)

“”

2002

Announcement of the strategic alliance with Roche and started business with Roche.

“”

2012

Established Chugai Pharmabody Research Pte. Ltd. In Singapore

“”

2018

Announcement of Business Expansion of Chugai Pharmabody Research Pte. Ltd.

Sir David Lane

Chairman of the Board

With its proprietary antibody engineering and cyclic peptide research technologies, CPR has great potential to create a world-leading technology platform that transforms the efficacy of antibody and cyclic-based drugs. At the same time, CPR can leverage on this technology to contribute to a community of innovation. Since its establishment, CPR has increasingly embedded itself into Singapore’s vibrant research scene through its research performance and involvement in external activities such as the organisation of antibody symposiums. As a result, expectations from others have also been increasing. I am very proud to help CPR generate a pipeline of innovative products that will help patients around the world. I am also pleased to help CPR foster closer interactions with Singapore’s international research community.